Chronic Obstructive Pulmonary Disease
Review shows supplementation only effective for baseline vitamin D levels 25 nmol/L.
Cognitive behavioral therapy delivered by respiratory nurses is associated with reduced anxiety symptoms and is cost-effective for patients with chronic obstructive pulmonary disease
Strong dose-response relationship seen in never-smokers aged 50 and older.
Elderly, those living 10 miles from facility, those with lower SES less likely to receive pulmonary rehab.
The most common error related to the use of metered dose inhalers was the failure to attach the inhaler to a spacer.
For patients with chronic obstructive pulmonary disease and comorbid posttraumatic stress disorder, long-term benzodiazepine use is not associated with mortality, but there is an association for short-term benzodiazepine use.
No difference in exacerbations with indacaterol/glycopyrronium for non-frequently exacerbating COPD.
Serologically assessed collagen remodeling plays a key role in the severity of COPD, as determined by airflow limitation and dyspnea, as well as in disease outcomes.
The use of formal palliative care services among patients with chronic obstructive pulmonary disease increased by 1% per year, going from 5.3% in 2004 to 14.3% in 2014.
A 55-year-old man with chronic obstructive pulmonary disease reports having some mild chest pain.
Researchers examined real-world characteristics of patients receiving albuterol multidose dry powder inhaler or short-acting β2 agonists with short-acting β2 agonists for asthma and chronic obstructive pulmonary disease.
Use of long-acting bronchodilators is linked to cardiovascular risks in patients with COPD.
A middle-aged patient with morbid obesesity and COPD complains about having shortness of breath at rest and dyspnea on exertion.
New evidence regarding safety is spurring the US FDA to remove a Boxed Warning from certain inhaled medications used to treat asthma and COPD.
Results support the benefits of single-inhaler triple therapy compared with inhaled corticosteroid/long-acting β2-agonist therapy in patients with advanced COPD.
The COPD Foundation has released tips for patients with COPD to avoid pneumonia and exacerbations.
Results show that exposure to pesticides and herbicides is associated with fixed airflow obstruction and chronic bronchitis.
Researchers found that doxycycline plus prednisone did not prolong the time between exacerbations in patients with COPD.
A chest CT can provide additional information on comorbidities, including coronary artery disease and osteoporosis.
Patients are more likely to exercise and participate in pulmonary rehabilitation if they live with others and have a caregiver.
LABA/LAMA is associated with a similar or lower risk of cardiovascular and cerebrovascular adverse events compared to treatment with LABA/inhaled corticosteroid.
Users of opioid-only agents had significantly increased rates of emergency room visits and hospitalizations for ischemic heart disease and IHD-related mortality.
Cardiac geometry demonstrated by non-contrast computerized tomography scan can predict which patients will respond to β-blocker therapy with a reduction in exacerbation frequency.
Adding home noninvasive ventilation to home oxygen therapy was effective in patients with persistent hypercapnia following an acute exacerbation of COPD.
The national action plan released by the NHLBI aims to reduce the burden of COPD through collaboration with federal agencies, patients, advocates, and researchers.
The TRINITY study found that triple therapy significantly reduced the rate of COPD exacerbations.
The annual number of patients who died from COPD while in the hospital decreased 62% from 2005 to 2014.
Distinct differences occur between eosinophilic COPD and COPD patients with asthma.
Increased residual volume is associated with a larger pulmonary artery in patients with COPD.
The use of inhaled corticosteroids is associated with an increased risk of pneumonia in asthma patients.